Commentary

Comment on “Skin Cancer Screening: The Paradox of Melanoma and Improved All-Cause Mortality”

Author and Disclosure Information

 

References

To the Editor:

I was unsurprised and gratified by the information presented in the Viewpoint on skin cancer screening by Ngo1 (Cutis. 2024;113:94-96). In my 30 years as a community dermatologist, I have observed that patients who opt to have periodic full-body skin examinations usually are more health literate, more likely to have a primary care physician (PCP) who has encouraged them to do so (ie, a conscientious practitioner directing their preventive care), more likely to have a strong will to live, and less likely to have multiple stressors that preclude self-care (eg, may be less likely to have a spouse for whom they are a caregiver) compared to those who do not get screened.

Findings on a full-body skin examination may impact patients in many ways, not only by the detection of skin cancers. I have discovered the following:

  • evidence of diabetes/insulin resistance in the form of acanthosis nigricans, tinea corporis, erythrasma;
  • evidence of rosacea associated with excessive alcohol intake;
  • evidence of smoking-related issues such as psoriasis or hidradenitis suppurativa;
  • cutaneous evidence of other systemic diseases (eg, autoimmune disease, cancer);
  • elucidation of other chronic health problems (eg, psoriasis of the skin as a clue for undiagnosed psoriatic arthritis); and
  • detection of parasites on the skin (eg, ticks) or signs of infection that may have notable ramifications (eg, interdigital maceration of a diabetic patient with tinea pedis).

I even saw a patient who had been sent for magnetic resonance imaging for back pain by her internist without any physical examination when she actually had an erosion over the sacrum from a rug burn!

When conducting full-body skin examinations, dermatologists should not underestimate these principles:

  • The “magic” of using a relatively noninvasive and sensitive screening tool—comfort and stress reduction for the patient from a thorough visual, tactile, olfactory, and auditory examination.
  • Human interaction—especially when the patient is seen annually or even more frequently over a period of years or decades, and especially when an excellent patient-physician rapport has been established.
  • The impact of improving a patient’s appearance on their overall sense of well-being (eg, by ­controlling rosacea).
  • The opportunity to introduce concepts (ie, educate patients) such as alcohol avoidance, smoking cessation, weight reduction, hygiene, diet, and exercise in a more tangential way than a PCP, as well as to consider with patients the idea that lifestyle modification may be an adjunct, if not a replacement, for prescription treatments.
  • The stress reduction that ensues when a variety of self-identified health issues are addressed, for which the only treatment may be reassurance.

I would add to Dr. Ngo’s argument that stratifying patients into skin cancer risk categories may be a useful measure if the only goal of periodic dermatologic evaluation is skin cancer detection. One size rarely fits all when it comes to health recommendations.

In sum, I believe that periodic full-body skin examination is absolutely beneficial to patient care, and I am not at all surprised that all-cause mortality was lower in patients who have those examinations. Furthermore, when I offer my healthy, low-risk patients the option to return in 2 years rather than 1, the vast majority insist on 1 year. My mother used to say, “It’s better to be looked over than to be overlooked,” and I tell my patients that, too—but it seems they already know that instinctively.

Recommended Reading

Circulating Tumor DNA Predicts Early Treatment Response in Patients With HER2-Positive Cancers
MDedge Dermatology
Consider Skin Cancer, Infection Risks in Solid Organ Transplant Recipients
MDedge Dermatology
Oncologists Voice Ethical Concerns Over AI in Cancer Care
MDedge Dermatology
No Routine Cancer Screening Option? New MCED Tests May Help
MDedge Dermatology
Most Targeted Cancer Drugs Lack Substantial Clinical Benefit
MDedge Dermatology
Keratoacanthoma, SCC Relatively Rare With PD-1/PD-L1 Inhibitors, Study Suggests
MDedge Dermatology
Few Cancer Survivors Meet ACS Nutrition, Exercise Guidelines
MDedge Dermatology
The Clinical Utility of Teledermatology in Triaging and Diagnosing Skin Malignancies: Case Series
MDedge Dermatology
The Burden of Skin Cancer in the Military Health System, 2017-2022
MDedge Dermatology
The DEA Plans to Reschedule Marijuana: What Happens Next?
MDedge Dermatology